✦ LIBER ✦

P016 FLEXIBILITY IN INTERVAL AND DOSING OF INFLIXIMAB ENABLES MAINTAINED RESPONSE OF PATIENTS WITH CROHN'S DISEASE

✍ Scribed by F. Schnitzler; H. Fidder; M. Ferrante; M. Noman; G. Van Assche; I. Hoffman; S. Vermeire; P. Rutgeerts

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

W1220 Flexibility in Interval and Dosing

✍ Schnitzler, Fabian; Fidder, Herma; Ferrante, Marc; Noman, Maja; Van Assche, Gert 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Doubling the infliximab dose versus halv

✍ Lior Katz; Javier P. Gisbert; Beth Manoogian; Kirk Lin; Casper Steenholdt; Geras 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 903 KB

Predictors of response to infliximab in

✍ Mansour A. Parsi; Jean–Paul Achkar; Scott Richardson; Jeffry Katz; Jeffrey P. Ha 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 94 KB

P397 Outcomes after dose escalation of i

✍ Sako, M.; Kawaguchi, T.; Hirayama, A.; Fukushi, G.; Hayama, K.; Fujiwara, T.; Yo 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 51 KB

P352 Need for infliximab dose intensific

✍ C. Taxonera; D. Olivares; J.L. Mendoza; M. Cañas; F. Estremera; M. Díaz-Rubio 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 61 KB

Discussion on predictors of response to

✍ Daan Hommes 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 91 KB